S113: NATIONAL PEGASPARGASE-MODIFIED RISK-ORIENTED PROGRAM FOR PHILADELPHIA-NEGATIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA (PH− ALL/LL). GIMEMA LAL 1913 FINAL RESULTS.

Podobne knjige/članki

• Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group
  od: Davide Lazzarotto, et al.
  Izdano: (2025-08-01)
• S113: NATIONAL PEGASPARGASE-MODIFIED RISK-ORIENTED PROGRAM FOR PHILADELPHIA-NEGATIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA (PH− ALL/LL). GIMEMA LAL 1913 FINAL RESULTS.
  od: R. Bassan, et al.
  Izdano: (2022-06-01)
• Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study
  od: Davide Lazzarotto, et al.
  Izdano: (2024-08-01)
• lal
  Izdano: (2019)
• P062 | OUTCOMES OF YOUNGER ADULT PATIENTS WITH PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH- ALL) OR LYMPHOBLASTIC LYMPHOMA (LL), TREATED IN THE REAL-LIFE WITH A PEDIATRIC-LIKE REGIMEN BASED ON GIMEMA LAL1308 PROTOCOL: A RETROSPECTIVE CAMPUS ALL STUDY.
  od: F. Forghieri, et al.
  Izdano: (2025-09-01)